| 2.44 0.09 (3.83%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.51 | 1-year : | 8.87 |
| Resists | First : | 5.57 | Second : | 7.59 |
| Pivot price | 2.61  |
|||
| Supports | First : | 2.29 | Second : | 1.91 |
| MAs | MA(5) : | 2.49 |
MA(20) : | 3.68 |
| MA(100) : | 6.47 |
MA(250) : | 7 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 4.9 |
| RSI | RSI(14): 26.5 |
|||
| 52-week | High : | 12.3 | Low : | 2.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LGVN ] has closed above bottom band by 20.3%. Bollinger Bands are 77.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.47 - 2.48 | 2.48 - 2.5 |
| Low: | 2.29 - 2.31 | 2.31 - 2.33 |
| Close: | 2.41 - 2.44 | 2.44 - 2.47 |
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Mon, 05 Oct 2026
Longeveron CEO Stephen H. Willard Discloses RSU Tax Withholding Share Disposal - Kalkine Media
Wed, 30 Sep 2026
A preprint suggests a cell therapy may reduce brain inflammation in Alzheimer’s - Stock Titan
Wed, 23 Sep 2026
Longeveron reports ELPIS II misses primary endpoint; to analyze data, explore strategic options - TradingView
Tue, 22 Sep 2026
Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value? - Yahoo Finance
Mon, 24 Aug 2026
Longeveron Announces 1-for-10 Reverse Stock Split - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.57e+006 (%) |
| Held by Institutions | 15.1 (%) |
| Shares Short | 153 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.244e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 150.1 % |
| Return on Equity (ttm) | -91 % |
| Qtrly Rev. Growth | 1.19e+006 % |
| Gross Profit (p.s.) | -141.08 |
| Sales Per Share | -588.4 |
| EBITDA (p.s.) | 2.86786e+006 |
| Qtrly Earnings Growth | -10 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.2 |
| Dividend | 0 |
| Forward Dividend | 169990 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|